The fungal infection pipeline has more than 60
drugs. In pipeline analysis, drugs are analyzed based on route of
administration and molecule type. The pipeline is also analyzed on the basis of
monotherapy and combination therapy, and different clinical phases including
Phase III, Phase II, Phase I and Pre-clinical stage.
Explore Report Sample
at: https://www.psmarketresearch.com/market-analysis/fungal-infections-pipeline-analysis/report-sample
Phase III clinical
trial known for the comparison of new treatments with the standard treatment in
which the safety, efficacy and side effects of new intervention is compared
with the already existing treatment. The Phase III clinical trial takes around 2-3
years to complete and the total number of participants vary from 100-1,000.
After the completion of Phase III stage, the company filed New Drug Application
to the regulatory authorities known as filed stage. There are 3 drugs for
fungal infection in Phase III clinical trial. Terbinafine, also known as
MOB-015, is a drug candidate of Moberg Pharma AB. The drug candidate is being developed
for the treatment of onychomycosis. In fungal infection, no drugs have been
registered for NDA filing.
VT-1161, a phase II drug candidate of Viamet Pharmaceuticals, Inc. for
the treatment of onychomycosis (Fungal Infection) and recurrent vulvovaginal
candidiasis. Phase II clinical trial is the second phase that answer safety,
efficacy and dosing of the new intervention. There are total 14 drugs present
in phase II trial of fungal infections. Phase II clinical trial take around 2
years to complete and between 100 – 120 patients participate in the Phase II
trial.
Explore Report at: https://www.psmarketresearch.com/market-analysis/fungal-infections-pipeline-analysis
PC945 is under development by Pulmocide Ltd. for the prevention and
treatment for aspergillosis in cystic fibrosis, lung transplant and allergic
bronchopulmonary aspergillosis. The drug candidate targets the cytochrome P450
C-14 alpha demethylase (CYP51) and inhibits its action. There are 8 drugs present
in Phase I clinical stage. In Phase I clinical trial, safety of the new
intervention is determined. The trial takes around 1-2 years to complete and the
total number of volunteers participating in the trial vary between 15 – 30.
Pipeline analysis provides description about the key companies
developing fungal infections drugs. Some of the key players actively involved
in the research and development are Moberg Pharma AB, Viamet Pharmaceuticals,
Inc., Pulmocide Ltd., Vyom Biosciences, NovaDigm Therapeutics Inc., Matinas
BioPharma Holdings Inc., Sol-Gel Technologies Ltd. and Eisai Co. Ltd.
Browse Other Related
report at: https://www.psmarketresearch.com/industry-report/pharmaceuticals
About P&S Market Research
P&S Market Research is a market
research company, which offers market research and consulting services for
various geographies around the globe. We provide market research reports,
industry forecasting reports, business intelligence, and research based
consulting services across different industry/business verticals.
As one of the top growing market
research agency, we’re keen upon providing market landscape and accurate
forecasting. Our analysts and consultants are proficient with business
intelligence and market analysis, through their interaction with leading
companies of the concerned domain. We help our clients with B2B market research
and assist them in identifying various windows of opportunity, and framing
informed and customized business expansion strategies in different regions.
Contact:
P&S Market Research
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
No comments:
Post a Comment